Table 2 Clinical characteristics of survival group and death group

Age (year) ^a

65.3 ± 9.1

68.0 ± 6.1

-0.72

0.48

BMI (kg/m²) ^a

25.2 ± 2.7

23.4 ± 3.1

1.45

0.17

Gender ^b

-

1.00

Male

11 (91.7)

8 (100.0)

Female

1 (8.3)

0 (0.0)

Pathological classification ^b

4.58

0.08

Adenocarcinoma

10 (83.3)

3 (37.5)

Squamous cell carcinoma

2 (16.7)

 4 (50.0)

Other types

0 (0.0)

 1 (12.0)

History of smoking ^b

9 (75.9)

8 (100.0)

-

 0.24

Smoking Index ^c

600 (112.5, 787.5)

850 (600, 1150)

-1.60

 0.11

Complicated with emphysema ^b

7 (58.3)

7 (87.5)

-

  0.33

SpO2@RA (%) ^a

97.4 ± 1.7

95.3 ± 1.6

2.89

 0.10

NSE (ng/ml) ^a

16.0 ± 2.8

15.9 ± 2.6

0.07

  0.95

CEA (ng/ml) ^c

3.5 (2.7, 5.7)

3.3 (2.9, 10.8)

-0.50

 0.62

Cyfra211 (ng/ml) ^c

3.3 (2.8, 3.7)

4.6 (3.7, 7.4)

-2.31

 0.02*

SCCAg (ng/ml) ^c

1.2 (0.8, 1.8)

1.3 (1.0, 2.3)

-1.03

 0.31

ProGRP (pg/ml) ^a

55.1 ± 17.2

47.6 ± 24.6

0.78

 0.45

Pulmonary function before operation ^a

FVC / Predicted Value (%)

87.9 (80.5, 98.5)

92.4 (81.3, 105.7)

-0.319

 0.75

DLCO / Predicted Value (%)

64.7 (61.1, 68.3)

56 (46, 79)

-0.472

 0.64

Staging of lung cancer ^b

8.81

 <0.01*

Stage I

10 (83.3)

  1 (14.3)

Stage II

1 (8.3)

  2 (28.6)

Stage III

1 (8.3)

 3 (42.9)

Stage IV

0 (0.0)

 1 (14.3)

Surgical modality ^b

-

  1.00

VATS

10 (90.9)

  8 (100.0)

VATS - Thoracotomy

1 (9.1)

  0 (0.0)

-

 0.64

Pulmonary lobectomy

9 (75.0)

  5 (62.5)

Wedge resection of pulmonary segment

3 (25.0)

 3 (37.5)

Antifibrotic therapy ^b

6 (25.0)

1 (12.5)

-

0.65